Tag: Andrew Holden
Long-term IN.PACT AV data show there is “definitely a place” for...
Matteo Tozzi (Varese, Italy) and Kate Steiner (Stevenage, UK) sat down with Vascular News at this year’s Charing Cross (CX) International Symposium (23–25 April,...
Serrenator Alto first-in-man PRELUDE study results presented at LINC 2018
Cagent Vascular, a developer of technology for vessel dilatation in cardiovascular interventions, has announced positive results from the first-in-human PRELUDE study of the company's...
Phase I/II SHIELD trial results with SB-030 in peripheral vascular disease...
Symic Bio has announced results from the phase I/II SHIELD trial evaluating SB-030, a locally administered therapeutic, in patients with peripheral vascular disease undergoing...
Andrew Holden: Nellix EVAS Global Forward Registry
Andrew Holden (Auckland City Hospital, Auckland, New Zealand) is one of the principal investigators of the Nellix EVAS FORWARD Global Registry. He explained to...
